Cell Biochemistry and Function,
Год журнала:
2024,
Номер
42(7)
Опубликована: Сен. 3, 2024
ABSTRACT
Diabetes
mellitus
(DM)
and
Alzheimer's
disease
(AD)
rates
are
rising,
mirroring
the
global
trend
of
an
aging
population.
Numerous
epidemiological
studies
have
shown
that
those
with
Type
2
diabetes
(T2DM)
increased
risk
developing
dementia.
These
degenerative
progressive
diseases
share
some
factors.
To
a
large
extent,
amyloid
cascade
is
responsible
for
AD
development.
Neurofibrillary
tangles
induce
neurodegeneration
brain
atrophy;
this
chain
reaction
begins
hyperphosphorylation
tau
proteins
caused
by
beta
(Aβ)
accumulation.
In
addition
to
these
processes,
it
seems
alterations
in
glucose
metabolism
insulin
signalling
lead
cell
death
reduced
synaptic
plasticity
AD,
before
onset
symptoms,
which
may
be
years
away.
Due
substantial
evidence
linking
resistance
researchers
coined
name
“Type
3
diabetes”
characterize
condition.
We
still
know
little
about
processes
involved,
even
though
current
animal
models
helped
illuminate
links
between
T2DM
AD.
This
brief
overview
discusses
IGF‐1
disorders
primary
molecular
pathways
connect
them.
The
presence
GSK‐3β
intriguing.
proteins'
association
pancreatic
β‐cell
failure
suggests
they
might
therapeutic
targets
both
disorders.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
26(1), С. 209 - 209
Опубликована: Дек. 30, 2024
Atrial
fibrosis
is
a
hallmark
of
atrial
cardiomyopathy
and
plays
pivotal
role
in
the
pathogenesis
fibrillation
(AF),
contributing
to
its
onset
progression.
The
mechanisms
underlying
are
multifaceted,
involving
stretch-induced
fibroblast
activation,
oxidative
stress,
inflammation,
coagulation
pathways.
Variations
types-reactive
replacement
fibrosis-are
influenced
by
patient-specific
factors
such
as
age,
sex,
comorbidities,
complicating
therapeutic
approaches.
heterogeneity
leads
distinct
electrophysiological
abnormalities
that
promote
AF
via
reentrant
activity
enhanced
automaticity
mechanisms.
Despite
advancements
imaging,
late
gadolinium
enhancement
CMR
electroanatomical
mapping,
challenges
accurately
quantifying
persist.
Emerging
strategies
include
antifibrotic
agents
targeting
renin-angiotensin-aldosterone
system,
novel
pathways
like
TGF-β
signaling,
cardio-metabolic
drugs
SGLT2
inhibitors
GLP-1
receptor
agonists.
Innovative
interventions,
including
microRNA
modulation
lipid
nanoparticle-based
therapies,
show
promise
but
require
validation.
Knowledge
gaps
remain
correlating
clinical
outcomes
with
patterns
optimizing
diagnostic
tools.
Future
research
should
focus
on
precise
phenotyping,
integrating
advanced
imaging
molecular
biomarkers,
conducting
robust
trials
evaluate
therapies'
efficacy
reducing
burden
related
complications.
Biomedicines,
Год журнала:
2024,
Номер
12(3), С. 657 - 657
Опубликована: Март 14, 2024
Diabetic
kidney
disease
(DKD)
is
a
substantial
complication
of
type
2
diabetes
(T2D),
presenting
challenges
in
chronic
(CKD)
management.
In
addition
to
traditional
and
recent
therapies,
including
angiotensin,
converting
enzyme
(ACE)
inhibitors,
angiotensin
receptor
blockers,
sodium-glucose
cotransporter
(SGLT2)
mineralocorticoid
antagonists,
the
evolution
antihyperglycemic
treatments
has
introduced
promising
agent,
glucagon-like
peptide-1
agonist
(GLP-1RA)
for
management
DKD.
GLP-1RAs
enhance
insulin
release
reduce
glucagon
release,
offering
novel
approach
DKD
This
review
analyzes
molecular
pathways
through
which
GLP1-RAs
confer
renal
protection
T2D
DKD,
are
complex
multifaceted.
They
include
modulation
hemodynamics,
antioxidative
anti-inflammatory
actions,
metabolic
regulation,
direct
cellular
effects.
These
mechanisms
highlight
GLP1-RA’s
potential
as
therapeutic
option
glycemic
control
or
indirect
function
diabetic
patients,
emphasizing
potentiality
dual
therapy,
with
cardiovascular
holistic
approach.
Clinical
evidence
supports
reducing
albuminuria
enhancing
outcomes,
highlighting
their
value
comprehensive
strategy.
Cell Biochemistry and Function,
Год журнала:
2024,
Номер
42(7)
Опубликована: Сен. 3, 2024
ABSTRACT
Diabetes
mellitus
(DM)
and
Alzheimer's
disease
(AD)
rates
are
rising,
mirroring
the
global
trend
of
an
aging
population.
Numerous
epidemiological
studies
have
shown
that
those
with
Type
2
diabetes
(T2DM)
increased
risk
developing
dementia.
These
degenerative
progressive
diseases
share
some
factors.
To
a
large
extent,
amyloid
cascade
is
responsible
for
AD
development.
Neurofibrillary
tangles
induce
neurodegeneration
brain
atrophy;
this
chain
reaction
begins
hyperphosphorylation
tau
proteins
caused
by
beta
(Aβ)
accumulation.
In
addition
to
these
processes,
it
seems
alterations
in
glucose
metabolism
insulin
signalling
lead
cell
death
reduced
synaptic
plasticity
AD,
before
onset
symptoms,
which
may
be
years
away.
Due
substantial
evidence
linking
resistance
researchers
coined
name
“Type
3
diabetes”
characterize
condition.
We
still
know
little
about
processes
involved,
even
though
current
animal
models
helped
illuminate
links
between
T2DM
AD.
This
brief
overview
discusses
IGF‐1
disorders
primary
molecular
pathways
connect
them.
The
presence
GSK‐3β
intriguing.
proteins'
association
pancreatic
β‐cell
failure
suggests
they
might
therapeutic
targets
both
disorders.
